Skip to main content

Dr. Kika Veljkovic, PhD, FCACB

Clinical Biochemist, LifeLabs

Assistant Clinical Professor (Adjunct), McMaster University, Hamilton, O.N.

Dr. Veljkovic joined LifeLabs as a Clinical Biochemist in 2012 and is currently the Interim Laboratory Director for the LifeLabs Sudbury site. She is focused on high volume biochemistry and immunoassays including developing, supporting and improving quality systems for multi-site technologies, specialized test interpretation, healthcare provider and patient consultations, and support in maintaining accreditation standards. She is involved in multiple projects, providing leadership in identification, evaluation and implementation of new technologies, and advice in implementation of new or revised test guidelines and protocols.

Dr. Veljkovic earned her medical degree from University of Belgrade, Serbia, and her PhD in hemostasis, thrombosis and vascular disease from McMaster University. She is a graduate of the McMaster Postdoctoral Training Program in Clinical Biochemistry and a fellow of the Canadian Academy of Clinical Biochemistry. Dr. Veljkovic is professionally involved with the Institute for Quality Management in Healthcare, as a member of the IQMH Endocrinology and Immunology Scientific Committee and the Gender Identity Working Group. Her past professional activities include serving as the Secretary-Treasurer on the Ontario Society of Clinical Chemists Council. Dr. Veljkovic has an interest in teaching and holds an academic appointment in the Department of Pathology and Molecular Medicine at McMaster University Faculty of Health Sciences. She has published over 20 scientific papers and conference abstracts and has presented at national and international conferences. Dr. Veljkovic has received several awards for research excellence, including major funding from Canadian Institutes of Health Research and the Heart and Stroke Foundation of Canada, and awards from The Canadian Society of Clinical Chemists and American Association for Clinical Chemistry.

 

 

FEEDBACK: Patients HCP